|
|
非小细胞肺癌免疫治疗耐药性因素研究进展
|
Abstract:
非小细胞肺癌(NSCLC)是肺癌的主要类型，其治疗是临床研究的重点。近年来，新型治疗方式尤其是免疫检查点抑制剂的应用为NSCLC患者带来了新的治疗希望。但免疫治疗的耐药性问题仍是制约其疗效的关键因素。免疫治疗耐药性包括两大类：原发性耐药性和继发性耐药性，主要涉及内源性耐药性和外源性耐药性两个方面。内源性耐药机制主要涉及基因组和蛋白质组特征、肿瘤抗原与抗原递呈等方面异常。外源性耐药机制则与肿瘤微环境、免疫检查点共抑制等因素密切相关。本研究概述了NSCLC免疫治疗耐药性影响因子因素及其最新研究进展。
Non-small cell lung cancer (NSCLC) is a major focus type of lung cancer, and its treatment is a key area of clinical research. In recent years, the application of novel treatment methods, especially immune checkpoint inhibitors, has brought new hope for improving the survival of NSCLC patients. However, the issue of resistance to immunotherapy remains a critical factor limiting its efficacy. Immunotherapy resistance includes two main categories: primary resistance and secondary resistance, primarily involving intrinsic and extrinsic resistance mechanisms. Intrinsic resistance mechanisms mainly involve abnormalities in genomic and proteomic characteristics, tumor antigens, and antigen presentation. Extrinsic resistance mechanisms are closely related to the tumor microenvironment and immune checkpoint co-inhibition. This study summarizes the influencing factors of NSCLC immunotherapy resistance and the latest research progress.
| [1] | Mathew, D., Marmarelis, M.E., Foley, C., Bauml, J.M., Ye, D., Ghinnagow, R., et al. (2024) Combined JAK Inhibition and PD-1 Immunotherapy for Non-Small Cell Lung Cancer Patients. Science, 384, Article 1329. Https://doi.org/10.1126/science.adf1329 |
| [2] | Li, S., Wang, A., Wu, Y., He, S., Shuai, W., Zhao, M., et al. (2023) Targeted Therapy for Non-Small-Cell Lung Cancer: New Insights into Regulated Cell Death Combined with Immunotherapy. Immunological Reviews, 321, 300-334. https://doi.org/10.1111/imr.13274 |
| [3] | 许帆, 刘瑶, 杨蕴, 等. 肺癌免疫治疗耐药的临床现状与研究进展[J]. 中国肿瘤临床, 2024, 51(12): 628-634. |
| [4] | 揭光灵, 牛晓敏. Orient-31模式讨论: 免疫治疗在驱动基因阳性的晚期NSCLC靶向耐药后的探索[J]. 循证医学, 2024, 24(3): 138-141. |
| [5] | 王衍鸿, 罗斌, 王卓, 等. 单细胞RNA测序技术在肺癌肿瘤微环境研究中的进展[J]. 中国肺癌杂志, 2024, 27(6): 441-450. |
| [6] | 陈薪如, 周彩存. 肺癌内科治疗临床研究十年回顾和现状[J]. 实用肿瘤杂志, 2024, 39(3): 209-218. |
| [7] | Wang, X., Qiao, Z., Aramini, B., Lin, D., Li, X. and Fan, J. (2023) Potential Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer. Cancer and Metastasis Reviews, 42, 661-675. https://doi.org/10.1007/s10555-022-10074-y |
| [8] | Pellini, B., Madison, R.W., Childress, M.A., Miller, S.T., Gjoerup, O., Cheng, J., et al. (2023) Circulating Tumor DNA Monitoring on Chemo-Immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 29, 4596-4605. https://doi.org/10.1158/1078-0432.ccr-23-1578 |
| [9] | 陈波, 阚连娣, 叶发青, 等. 间变性淋巴瘤激酶在治疗非小细胞肺癌中的作用及潜在医学应用[J]. 中国药理学通报, 2024, 40(3): 415-420. |
| [10] | 刘险. 免疫检查点到个体化治疗策略的肺癌免疫治疗临床现状与进展[J]. 中国医学创新, 2024, 21(7): 179-183. |
| [11] | Miao, D., Zhao, J., Han, Y., Zhou, J., Li, X., Zhang, T., et al. (2023) Management of Locally Advanced Non-Small Cell Lung Cancer: State of the Art and Future Directions. Cancer Communications, 44, 23-46. https://doi.org/10.1002/cac2.12505 |
| [12] | Cai, R., Zhu, H., Liu, Y., Sha, H., Peng, W., Yin, R., et al. (2023) To Be, or Not to Be: The Dilemma of Immunotherapy for Non-Small Cell Lung Cancer Harboring Various Driver Mutations. Journal of Cancer Research and Clinical Oncology, 149, 10027-10040. https://doi.org/10.1007/s00432-023-04919-4 |
| [13] | Attieh, F., Chartouni, A., Boutros, M., Mouawad, A. and Kourie, H.R. (2023) Tackling the Immunotherapy Conundrum: Advances and Challenges for Operable Non-Small-Cell Lung Cancer Treatment. Immunotherapy, 15, 1415-1428. https://doi.org/10.2217/imt-2023-0128 |
| [14] | Goulart, B.H.L., Mushti, S.L., Chatterjee, S., Larkins, E., Mishra-Kalyani, P.S., Pazdur, R., et al. (2024) Correlations of Response Rate and Progression-Free Survival with Overall Survival in Immunotherapy Trials for Metastatic Non-Small-Cell Lung Cancer: An FDA Pooled Analysis. The Lancet Oncology, 25, 455-462. https://doi.org/10.1016/s1470-2045(24)00040-8 |
| [15] | Dunne, E.G., Fick, C.N., Isbell, J.M., Chaft, J.E., Altorki, N., Park, B.J., et al. (2024) The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery, 118, 119-129. https://doi.org/10.1016/j.athoracsur.2024.01.024 |
| [16] | Zhang, C., Qin, J., Zhao, X., Yang, L. and Wang, Z. (2024) A Commentary on ‘Impact of Lymphadenectomy Extent on Immunotherapy Efficacy in Postresectional Recurred Non-Small Cell Lung Cancer: A Multi-Institutional Retrospective Cohort Study’. International Journal of Surgery, 110, 4437-4438. https://doi.org/10.1097/js9.0000000000001347 |
| [17] | 邢晶, 尉姗, 王华英, 等. 蛋白泛素化修饰及相关药物在肺癌治疗中的研究进展[J]. 现代实用医学, 2023, 35(11): 1401-1404. |
| [18] | 韦坤辰, 吴骏峰, 唐昊. 免疫治疗在EGFR突变非小细胞肺癌中的研究进展[J]. 重庆医科大学学报, 2023, 48(11): 1282-1289. |
| [19] | D’Aiello, A., Stiles, B., Ohri, N., Levy, B., Cohen, P. and Halmos, B. (2024) Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges. Clinical Lung Cancer, 25, 197-214. https://doi.org/10.1016/j.cllc.2024.02.004 |
| [20] | Anagnostou, V., Ho, C., Nicholas, G., Juergens, R.A., Sacher, A., Fung, A.S., et al. (2023) ctDNA Response after Pembrolizumab in Non-Small Cell Lung Cancer: Phase 2 Adaptive Trial Results. Nature Medicine, 29, 2559-2569. https://doi.org/10.1038/s41591-023-02598-9 |
| [21] | Yin, S., Yu, Y., Wu, N., Zhuo, M., Wang, Y., Niu, Y., et al. (2024) Patient-Derived Tumor-Like Cell Clusters for Personalized Chemo and Immunotherapies in Non-Small Cell Lung Cancer. Cell Stem Cell, 31, 717-733.e8. https://doi.org/10.1016/j.stem.2024.03.008 |
| [22] | O’Brien, J. and Bodor, J.N. (2023) Perioperative Immunotherapy in Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 24, 1790-1801. https://doi.org/10.1007/s11864-023-01160-6 |
| [23] | Sequeira, T. and Almodovar, M.T. (2023) Immunotherapy in Non-small Cell Lung Cancer: a Review. Portuguese Journal of Cardiac Thoracic and Vascular Surgery, 30, 55-65. |
| [24] | Shirasawa, M., Yoshida, T. and Ohe, Y. (2023) Biomarkers of Immunotherapy for Non-Small Cell Lung Cancer. Japanese Journal of Clinical Oncology, 54, 13-22. https://doi.org/10.1093/jjco/hyad134 |
| [25] | 张嘉涛, 潘燚, 汪斌超, 等. Adaptive Treatment: 肺癌治疗的加加减减[J]. 循证医学, 2024, 24(1): 1-11. |
| [26] | 刘思健, 瞿理, 张玲, 等. m~6A RNA修饰在非小细胞肺癌治疗耐药中作用及机制的研究进展[J]. 现代肿瘤医学, 2024, 32(8): 1531-1537. |
| [27] | 鲁葆华, 李琨, 张婵, 等. 老年EGFR突变非小细胞肺癌耐药后PD-1抑制剂免疫治疗37例临床分析[J]. 临床肺科杂志, 2023, 28(11): 1716-1722. |
| [28] | 张可心, 郝娜, 王丽萍. 免疫检查点抑制剂在奥希替尼耐药非小细胞肺癌治疗中的应用[J]. 肿瘤基础与临床, 2023, 36(5): 378-382. |
| [29] | 李梦超, 吕垚, 唐希阳, 等. 肺癌细胞外基质物理性质对疾病发生、发展和免疫微环境的影响[J]. 现代免疫学, 2023, 43(3): 239-244. |
